Caribou Biosciences (CRBU) Operating Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Operating Expenses data on file, last reported at $28.7 million in Q1 2026.

• Quarterly Operating Expenses fell 36.65% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $142.9 million (down 17.6% YoY) and the FY2025 annual result came in at $159.5 million, down 9.69% from the prior year.
• Operating Expenses retreated to $28.7 million in Q1 2026 per CRBU's latest filing, from $32.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $50.2 million in Q2 2025 and bottomed at $23.5 million in Q1 2022.
• The 5-year median for Operating Expenses is $36.6 million (2023), against an average of $37.4 million.
• The widest annual swing landed in 2022, when Operating Expenses surged 87.06%; it then plunged 36.65% in 2026.
• Tracing CRBU's Operating Expenses over 5 years: stood at $34.3 million in 2022, then grew by 19.64% to $41.0 million in 2023, then declined by 0.12% to $41.0 million in 2024, then retreated by 20.9% to $32.4 million in 2025, then slipped by 11.47% to $28.7 million in 2026.
• Per Business Quant, the three latest CRBU Operating Expenses figures stand at $28.7 million (Q1 2026), $32.4 million (Q4 2025), and $31.6 million (Q3 2025).

Peer Comparison